Company profile: Statera Biopharma
1.1 - Company Overview
Company description
- Provider of biotechnology research services and immune-restorative drug development, advancing STAT-201 for pediatric Crohn's, STAT-205 for acute and post-acute COVID-19, STAT-401 as an adjunct for pancreatic cancer, the AIMS platform targeting complex pathways and toll-like receptors, and Entolimod, a TLR5 agonist for radio-mitigation in cancer patients.
Products and services
- AIMS (ADVANCED IMMUNOMODULATING MULTI-COMPONENT SYSTEM): A modular development platform that architects immune-restorative drugs by targeting complex pathways and engaging toll-like receptors
- STAT-201: An investigational drug candidate engineered to treat pediatric Crohn's disease by restoring mucosal healing and strengthening intestinal barrier function
- STAT-205: A research-stage therapy developed to address acute and post-acute COVID-19 infections by modulating immune system function
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Statera Biopharma
Apellis
HQ: United States
Website
- Description: Provider of novel therapeutics and drug delivery technologies for chronic inflammatory diseases, with approved treatments SYFOVRE for geographic atrophy (a form of age-related macular degeneration) and EMPAVELI for paroxysmal nocturnal hemoglobinuria; conducts clinical trials for IC-MPGN and C3G, HSCT-TMA, and CAD; and offers compassionate use and early access programs for investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apellis company profile →
Escient Pharmaceuticals
HQ: United States
Website
- Description: Provider of bio-technical research and development services focused on advancing first-in-class G Protein-Coupled Receptor targeted drugs and therapies for neuro-immuno-inflammatory and autoreactive diseases. Pipeline includes EP262, an oral, once-daily small molecule MRGPRX2 antagonist for the potential treatment of mast cell-mediated diseases (including chronic urticarias and atopic dermatitis), and EP547, an oral, once-daily MRGPRX4 antagonist for cholestatic and uremic pruritus.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Escient Pharmaceuticals company profile →
Alladapt
HQ: United States
Website
- Description: Provider of prescription therapeutics targeting food allergy; a privately held biopharmaceutical company focused on developing such treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alladapt company profile →
vTv Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule therapeutics addressing unmet medical needs, including: TTP399, a liver-selective glucokinase activator adjunct to insulin for type 1 diabetes to reduce hypoglycemia; HPP737, a PDE4 inhibitor for psoriasis with potential in COPD and atopic dermatitis; TTP273, an oral GLP-1 receptor agonist for type 2 diabetes; and a Nrf2/Bach1 program to reduce oxidative stress and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full vTv Therapeutics company profile →
Medsenic
HQ: France
Website
- Description: Provider of drug development and manufacturing focused on drugs for the treatment of autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medsenic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Statera Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Statera Biopharma
2.2 - Growth funds investing in similar companies to Statera Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Statera Biopharma
4.2 - Public trading comparable groups for Statera Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →